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Abstract
Introduction Anaemia during chemotherapy is often left
untreated. Erythropoiesis-stimulating agents are frequently
used to treat overt anaemia. Their prophylactic use,
however, remains controversial and raises concerns about
cost-effectiveness. Therefore, we assessed the efficacy of a
dose-reduction schedule in anaemia prophylaxis.
Materials and methods The study included patients with
untreated solid tumours about to receive platinum-based
chemotherapy and had haemoglobin (Hb) levels ≥11 g/dL.
Epoetin-α was administered at a dose level of 3×10,000 U
weekly as soon as Hb descended to < 13 g/dL. Dose
reductions to 3×4,000 U and 3×2,000 U weekly were
planned in 4-week intervals if Hb stabilised in the range of
11–13 g/dL. Upon ascending to ≥13 g/dL, epoetin was
discontinued. Iron supplements of 100 mg intravenous
doses were given weekly. Of 37 patients who enrolled, 33
could be evaluated.
Results and discussion Their median Hb level was 13.7
(10.9–16.2) g/dL at baseline and descended to 11.0
(7.4–13.8) g/dL by the end of chemotherapy. Anaemia
(Hb<10 g/dL) was prevented in 24 patients (73%). The
mean dose requirement for epoetin-α was 3×5,866 U per
week per patient, representing a dose reduction of 41%.
Treatment failed in nine patients (27%), in part due to
epoetin-α resistance in four (12%) and blood transfusion in
three (9%) patients.
Conclusion Dose reduction was as effective as fixed doses
in anaemia prophylaxis but reduced the amount of
prescribed epoetin substantially.
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Introduction
Anaemia is commonly observed in cancer patients. The
prevalence is 39% at the time of diagnosis. During
chemotherapy, the incidence has been shown to reach
63% [28] and increases with the number of chemotherapy
cycles. Incidence of anaemia is also higher in lung (71%) or
gynaecological (65%) cancers [22]. Management of anae-
mia, including the use of erythropoietin proteins, varies
widely. The majority of cases (61%) are left untreated. Only
17% of cases are treated with epoetin and 15% with blood
transfusions.
Major oncological societies have issued guidelines for
the management of anaemia, notably including the
American Society of Clinical Oncology [33], the Na-
tional Comprehensive Cancer Network [1], and the
European Organization of Research and Treatment of
Cancer [2, 11, 35]. Treatment with erythropoiesis-
stimulating agents (ESA’s) is recommended for anaemic
patients (Hb<10 g/dL) on chemotherapy and/or radiother-
apy. For patients with declining Hb levels but less severe
anaemia (Hb<12 g/dL), clinical circumstances such as Hb
levels prior to cancer treatment shall be considered before
initiation of ESA’s. Recent guideline updates recommend
Hb target levels of 12 g/dL with a view to improve quality
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of life and minimise the risk of blood transfusion. Despite
these recommendations, half of all patients affected do not
receive treatment, leading to impaired quality of life and
potentially decreased survival [12, 27, 28, 43].
Furthermore, the management of anaemia focuses
mainly on the treatment of cancer or chemotherapy-
induced anaemia and only to a lesser extent on the
prevention of chemotherapy-induced anaemia. However,
there is some evidence from unblinded studies that
immediate versus delayed initiation of erythropoietin-
stimulating agents at a Hb threshold can reduce the
transfusion rate and improve scores on physical and
functional well-being [17, 33, 39].
The usual dose regimen for epoetin-α is either 10,000 U
(150 U/kg) administered three times a week or 40,000 U once
a week. Longer dosing intervals (every 2 or 3 weeks) using
modified ESA’s with longer half life are equally efficacious
[37]. ESA’s administration should be temporarily discon-
tinued if target values are exceeded but should be reinforced
in the absence of a Hb response. Findings from several
randomised studies and meta-analyses demonstrate that
ESA’s are capable of both raising Hb levels by ≥2 g/dL in
53% of patients and reducing the risk of blood transfusions
from 23–65% to 9–36% [26, 42]. These outcomes are
associated with improved health-related quality of life and
reduced symptoms after controlling for clinical and demo-
graphic aspects [8, 10, 13, 18, 21, 31, 34, 36].
Concerns on the use of ESA’s have been raised of an
increased risk of venous thromboembolic events (VTEs) and
mortality [7]. The higher incidence of VTEs might be due to
a high haematocrit and elevated viscosity and therefore
controlled by limiting the target Hb levels [38]. A recent
meta-analysis on individual patient data estimated a 17%
increase in mortality rate in cancer patients [9]. Recent
reports also suggest that the erythropoietin receptor on
cancer cells may play a role in promoting cell proliferation
and survival [3, 24, 25]. These findings emphasise the need
to monitor Hb levels closely and also to use the lowest dose
of ESA’s required to maintain the target level.
ESA’s also impose a substantial burden on hospital
budgets and the entire healthcare systems. Use of these
agents has been estimated to account for over 10% of total
expenses for cancer care [19, 29]. Therefore, any strategy
that enables better control of epoetin administration would
be highly welcomed. Our goal is to develop a strategy that
will reduce the dose requirements for ESA’s to the lowest
level while still offering effective prophylaxis of
chemotherapy-induced anaemia.
The objective of the present study was to evaluate the
efficacy of a dose-reduction schedule for epoetin-α admin-
istered in conjunction with an intravenous iron supplement
to prevent anaemia (defined as Hb<10 g/dL) during
platinum-based chemotherapy in high-risk patients [22].
Patients and methods
Inclusion criteria Patients (≥18 years old) were recruited
at the Centre Pluridisciplinaire d’Oncologie, Lausanne,
Switzerland and at the Department of Oncology,
University of Basel, Switzerland. All patients gave
written informed consent. Histological diagnosis of solid
tumours was confirmed in all cases. None of the
tumours had been treated previously. All patients were
scheduled to receive at least three cycles of platinum-
based chemotherapy with minimum doses of 60 mg/m²
cisplatin every 3 weeks or carboplatin (AUC=5) every
3 weeks. Further requirements included Hb levels ≥
11 g/dL, creatinine clearance ≥ 60 ml/min, ECOG
performance ≤ 2 and life expectancy ≥ 3 months.
Exclusion criteria Patients were excluded from the study if
severe co-morbidities or active pulmonary, gastrointestinal
and/or genitourinary bleeding were present. Other criteria
leading to exclusion from the study were uncontrolled
hypertension (diastolic blood pressure > 100 mmHg); history
of seizures; known hypersensitivity to recombinant human
erythropoietin or iron (III)-hydroxide sucrose complex;
transfusion less than 2 weeks before study entry; acute major
illness or infection less than 1 month before study entry; and
any previous chemotherapy or radiotherapy.
Treatment with epoetin and dose adjustment Starting on the
first day of chemotherapy, 10,000 U epoetin-α were admin-
istered subcutaneously three times a week. Patients exhibiting
Hb levels ≥ 13 g/dL at baseline were re-examined every
4 weeks and would receive subcutaneous epoetin-α only if Hb
fell under 13 g/dL. Doses were adjusted every 4 weeks based
on Hb levels. Treatment was temporarily discontinued on
reaching the target level of ≥13 g/dL and was resumed
4 weeks later at the previous dose level if the level once again
descended to <13 g/dL. In the event that Hb levels stabilised in
the range of 11–13 g/dL, the dose was reduced from 10,000 to
4,000 U, or from 4,000 to 2,000 U, over the next 4 weeks. Hb
levels descending to <11 g/dL were handled by increasing the
dose to the next higher dose level (10,000 to 20,000 U) over
the next 4 weeks. Epoetin-α was discontinued in patients
classified as non-responders.
Epoetin-α was administered throughout the scheduled
duration of chemotherapy until 3 weeks after the last
injection. The same timetable was used if chemotherapy
was prematurely discontinued due to tumour progression or
unacceptable toxicity.
Iron was administered intravenously once weekly in the
form of iron (III)-hydroxide sucrose complex at a dose level
of 100 mg to all patients irrespective of ferritin levels. No
additional iron doses were administered once epoetin-α had
been discontinued. Erythrocyte transfusions were per-
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formed if Hb levels dropped below 8 g/dL; otherwise this
option was left to the discretion of the physician in charge.
The protocol was approved by the local ethical commit-
tee of the two centres participating in the study.
Assessment of study endpoints The main objective of the
study was to prevent anaemia defined as Hb<10 g/dL. A
secondary endpoint was to assess the mean weekly dose of
epoetin-α administered during chemotherapy treatment.
Transfusion requirements were also documented. Complete
blood counts were obtained weekly throughout treatment.
Ferritin levels were measured at baseline and at the end of
treatment. Patients were only evaluated if treatment had
been carried on for at least 6 weeks. Resistance to epoetin-
α was assumed in the presence of persistent Hb levels of
<10 g/dL over 4 weeks of treatment at a dose level of
20,000 U. Hb<10 g/dL or transfusion was also defined as
treatment failure.
Statistical methods The null hypothesis for the primary
endpoint would be rejected if the treatment with epoetin-α
prevents anaemia (Hb<10 g/dL) in over 70% of patients
compared with 50% in patients undergoing similar (cisplat-
in-based) treatment without epoetin-α. The sample size
required to test this hypothesis was 37 patients (one-sided
hypothesis: α=0.05; power: β=0.2) according to Fleming
[20]. Thus anaemia had to be effectively prevented in over
22 patients for the null hypothesis to be rejected.
Results
In total, 37 patients were enrolled in the study between
April 1999 and September 2002. Pertinent patient charac-
teristics are summarised in Table 1. The cohort included 26
men and 11 women with a median age of 58 years (range
36–69). The majority of these patients had lung cancer
(n=28) and was treated with cisplatin (n=33). Patients were
treated with a median number of four cycles of chemother-
apy (range 1–6).
At baseline, the median Hb level was 13.7 g/dL (range
10.9–16.2) and median ferritin level was 204 μg/L (range
22–988).
Four patients were excluded from efficacy analysis. Two
of them never received epoetin-α, one due to treatment
refusal after enrolment and another due to chemotherapy-
related haemolysis. The other two patients could not be
evaluated because of intercurrent adverse events: one
patient died of myocardial infarction on day 16 after having
received seven injections of epoetin-α (Hb=14.6 g/dL); and
the other patient suffered transient cerebral ischemia on day
7 after having received three injections of epoetin-α
(Hb=12 g/dL).
At baseline, 21 of 33 patients (64%) had Hb levels ≥
13 g/dL. Treatment with epoetin-α was initiated after 4 or
8 weeks in all but one of these patients when Hb levels
dropped below 13 g/dL. Only one patient never required
epoetin-α. For 12 patients with baseline Hb level of
11–13 g/dL, epoetin-α was started concomitantly with the
first cycle of chemotherapy.
At the end of therapy, the median Hb level was down to
11.0 g/dL (range 7.4–13.8).
Anaemia with Hb<10 g/dL was prevented in 24 patients
(73%). Despite epoetin-α treatment, nine patients devel-
oped anaemia (Hb<10 g/dL) but all had Hb≥8 g/dL.
Treatment failed in nine patients (27%). These failures
included resistance to epoetin-α in four cases (12 %)
despite an increased epoetin-α dose of 20,000 U three times
per week, blood transfusion in three cases (9%) and
premature end of treatment with Hb level <10 g/dL in
two cases (6%).
All patients Evaluable patients
N 37 33
Men/women 26/11 22/11
PS≤½ 34/3 30/3
Median age 58 (36–69) 58 (40–68)
NSCLC 22 (59%) 18 (56%)
SCLC 6 (16%) 6 (18%)
Testicular cancer 2 (6%) 2 (7%)
Bladder carcinoma 2 (6%) 2 (7%)
Other carcinomaa 4 (11%) 4 (12%)
Regimen with DDP≥75 mg/m2 33 29
Regimen with CBDCA AUC 5 4 4
Median chemotherapy cycles 4 cycles (1–6) 4 cycles (1–6)
Median Hb at baseline (g/dl) 13.7 (10.9–16.2) 13.7 (10.9–16.2)
Table 1 Patient characteristics
DDP cisplatin, CBDCA
carboplatin
a Ovarian carcinoma, unknown
primary, urachus carcinoma,
neuroendocrine pancreatic
carcinoma, mediastinal
carcinoma all 1
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Epoetin-α was administered for a median of 8 (0–20)
weeks.
Dose levels could be effectively reduced from 10,000 to
4,000 U or less in ten patients (30%). Doses were increased
to 20,000 U in seven patients (21%). The median dose level
of epoetin-α used was 5,866 U three times per week.
No adverse events related to the intravenous iron
supplements were reported. The median ferritin level was
941 μg/L (range 346–1275) at the end of treatment.
Discussion
Our data demonstrate that a 30% reduction of the epoetin-α
dose can be achieved in patients with anaemia induced by
platinum-based chemotherapy. Anaemia was effectively pre-
vented in 24 of 33 patients (73%) using the dose-reduction
schedule described above. The mean dose requirement of
5,866 U three times per week per patient was 41% below the
recommended standard dose. These findings support current
recommendations for a dose decrease to reduce the risk of
thrombovascular events associated with ESA’s treatment [33].
To our knowledge, this is the first study to explore the
lowest epoetin-α dose level that effectively prevents
anaemia (defined as Hb level < 10 g/dL) induced by
platinum-based chemotherapy. A previous randomised
study included 130 small-cell lung center patients with Hb
levels > 10.5 g/dL who were treated three times a week with
epoetin-α 150 U/kg (10,000 U) or 300 U/kg (20,000 U) or
received no treatment [40]. A total of 66% of patients in the
control group exhibited anaemia (Hb<10 g/dL) compared
with 48% and 39%, respectively, in the two treatment
groups. Transfusions were performed in 59%, 45% and
20% of patients, respectively. Administration of ESA’s was
temporarily discontinued when Hb levels reached >15 g/dL
and was resumed with the dose reduced by half upon Hb
relapsing to ≤13 g/dL. Thus, the mean weekly doses in the
two treatment groups were 335 and 612 U/kg (equivalent to
7,500 and 13,600 U three times weekly), representing a
dose reduction of 25% and 32%, respectively.
In another randomised trial of epoetin-α, a mean dose
level of 10,000 U three times weekly prevented anaemia
(Hb<10 g/dL) in 83% of patients, and the transfusion rate
was 15% [5]. The same efficacy was demonstrated with a
dose administration of 40,000 U once weekly, which
effectively controlled anaemia in 82% of patients, with
12% requiring transfusion [15]. Our low transfusion rate
(9%) is possibly the result of a fairly restrictive transfusion
policy. Transfusions were only prescribed when Hb levels
fell to < 8 g/dL and were otherwise left to the discretion of
the physician in charge. A similar transfusion rate (8.6%)
was obtained in a randomised study that also evaluated
anaemia prevention with similar transfusion guidelines as
ours [14]. In that study, weekly doses of 40,000 U epoetin-
α were decreased by 25%. Doses were withheld when Hb
levels reached >14 g/dL in 29% of patients or were
increased (to 60,000 U) in 9% of patients.
The efficacy findings in our trial are similar to those
reported in the cited studies despite notably different target
Hb levels and a different general strategy. This demon-
strates that the reduction strategy we adopted was not
detrimental to achieving target Hb levels.
One factor that may have contributed to our results was
the concomitant weekly intravenous administration of iron.
The benefit of parenteral iron had been demonstrated in a
number of controlled randomised trials [4, 6, 23, 41]. In
157 anaemic cancer patients undergoing chemotherapy, iron
supplements to epoetin-α, administered either orally at
650 mg/day or intravenously at 100 mg weekly, increased
Hb levels by 1.5 or 2.5 g/dL, respectively, compared with
0.9 g/dL in the placebo group [4].
In our study, two serious vascular events were reported after
the initial doses of epoetin-α and were considered unrelated to
the study medication by the treating physicians on the basis
that the patients’ Hb levels remained within normal range.
Indirect toxicity of epoetin-α, however, cannot be excluded.
These two patients were treated for advanced non-small cell
lung cancer and a high rate of cardiovascular events has been
documented to occur frequently in this patient population [30].
Although our Hb target of 13 g/dL is higher than current
recommendations, the median Hb level (11 g/dL) reached at
the end of the treatment period is considered safe.
Our findings and those of the cited studies show that the
intensity and thereby the economic burden of ESA’s
treatment could be substantially decreased if appropriate
dose-reduction strategies together with intravenous iron
supplements were to be widely adopted. Finally, a dose-
reduction strategy with stringent rules (target Hb≤12 g/dL)
is also important given the controversially discussed the
impact of epoetins on survival [7, 16, 32].
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